No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome

Judith M. Poldervaart*, Emma Rottger, Marieke S. Dekker, Nicolaas P. A. Zuithoff, Peter W. H. M. Verheggen, Evelyn A. de Vrey, Thierry X. Wildbergh, Arnoud W. J. van 't Hof, A Mosterd, Arno W. Hoes

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background

Despite the availability of high-sensitive troponin (hs-cTnT), there is still room for improvement in the diagnostic assessment of patients suspected of acute coronary syndrome (ACS). Apart from serial biomarker testing, which is time-consuming, novel biomarkers like copeptin have been proposed to expedite the early diagnosis of suspected ACS in addition to hs-cTnT. We determined whether placenta derived growth factor (PlGF), soluble Fms-like tyrosine kinase 1 (sFlt-1), myoglobin, N-terminal prohormone B-type Natriuretic Peptide (NT-proBNP), growth-differentiation factor 15 (GDF-15) and copeptin improved early assessment of chest pain patients.

Methods

This prospective, single centre diagnostic FAME-ER study included patients presenting to the ED with symptoms suggestive of ACS. Blood was collected to measure biomarkers, notably, hs-cTnT was retrospectively assessed. Added value of markers was judged by increase in AUC using multivariable logistic regression.

Results

Of 453 patients enrolled, 149 (33%) received a final diagnosis of ACS. Hs-cTnT had the highest diagnostic value in both univariable and multivariable analysis. PPVs of the biomarkers ranged from 23.5% (PlGF) to 77.9% (hs-cTnT), NPVs from 67.0% (PlGF) to 86.4% (hs-cTnT). Only myoglobin yielded diagnostic value in addition to clinical symptoms and electrocardiography (ECG) (AUC of clinical model 0.80) with AUC of 0.84 (p

Conclusion

When assessing patients suspected of ACS, only myoglobin had added diagnostic value beyond clinical symptoms and ECG. However, when combined with hs-cTnT, it yields no additional diagnostic value. PlGF, sFlt-1, NT-proBNP, GDF-15 and copeptin had no added value to the clinical model or hs-cTnT.

Original languageEnglish
Article number0132000
Number of pages14
JournalPLoS ONE [E]
Volume10
Issue number7
DOIs
Publication statusPublished - 15 Jul 2015

Keywords

  • ACUTE MYOCARDIAL-INFARCTION
  • ACUTE CHEST-PAIN
  • GROWTH-DIFFERENTIATION FACTOR-15
  • RISK STRATIFICATION
  • UNIVERSAL DEFINITION
  • TROPONIN-T
  • RAPID RULE
  • COPEPTIN
  • ASSUMPTIONS

Fingerprint

Dive into the research topics of 'No Added Value of Novel Biomarkers in the Diagnostic Assessment of Patients Suspected of Acute Coronary Syndrome'. Together they form a unique fingerprint.

Cite this